Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective,Single-arm,and Exploratory Phase II Clinical Study for the Efficacy of Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Squamous Cell Carcinoma After Radical Resection

NCT03913182 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT03913182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective,Single-arm,and Exploratory Phase II Clinical Study for the Efficacy of Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Squamous Cell Carcinoma After Radical Resection
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 2, 2019
Completion date
May 30, 2021
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, esophageal squamous cell carcinoma, metastasis, recurrence